This finding suggested that the HIF-1 signaling pathway plays a critical role in the transition between the two Treg cell clusters, ultimately influencing the anti-tumor immune response in patients with pancreatic cancer and leading to divergent prognosis outcomes. This evidence concerns the gene HIF1A and familial pancreatic carcinoma.